The value of tumor markers in prediction of ovarian cancer prognosis.

doi:10.7504/fk2015020112

Abstract

Abstract:

Abstract:A precise prediction of tumor prognosis is essential to promoting the individualized therapy for ovarian cancer. Both protein and non-coding RNA are potential predictive factors, and a series of tumor markers have been proved to be significantly associated with overall survival, progression-free survival and/or response to chemotherapy in patients with ovarian cancer. However, further validations are required before any of the biomarkers can be applied to clinical prediction.

Key words: ovarian cancer, tumor marker, prognosis, survival, response to chemotherapy

摘要：

对卵巢癌预后进行准确预测是个体化治疗的基础和推动力。无论蛋白还是非编码RNA，都有作为卵巢癌预后预测因子的潜能。已经研究证实其中的一些肿瘤标志物与卵巢癌的总生存、无进展生存和（或）化疗反应性密切相关，但在用于临床之前还需要进一步验证。

关键词: 卵巢癌, 肿瘤标志物, 预后, 生存, 化疗反应性

CLC Number:

R737.3

CAI Jing, WANG Ze-hua.. The value of tumor markers in prediction of ovarian cancer prognosis.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015020112.

蔡晶，王泽华. 肿瘤标志物预测卵巢癌预后的价值[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015020112.

References

［1］   Braicu EI, Fotopoulou C, Van Gorp T, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients:results from the OVCAD study［J］. Gynecol Oncol,2012,128:245-251.

［2］   Angioli R, Plotti F, Capriglione S, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? ［J］.Gynecol Oncol,2013,128:579-583.

［3］   Angioli R, Capriglione S, Aloisi A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?［J］.Tumour Biol,2014 ,35(7):7009-7015.

［4］   Xu L, Cai J, Yang Q, et al. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies［J］. J Cancer Res Clin Oncol，2013，139(8):1257-1277.

［5］   Cai J, Xu L, Tang H, et al. The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis［J］. Oncologist，2014，19(5):528-535.

［6］   Cao J, Cai J, Huang D, et al. miR-335 represents an independent prognostic marker in epithelial ovarian cancer［J］. Am J Clin Pathol，2014，141(3):437-442.

［7］   Lee H, Park CS, Deftereos G, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features［J］. World J Surg Oncol，2012，10:174.

［8］   Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma［J］. Clin Cancer Res，2008，14:2690-2695.

［9］   Davidson B, Tropé CG, Reich R.The clinical and diagnostic role of microRNAs in ovarian carcinoma［J］. Gynecol Oncol，2014，133(3):640-646.

［10］   Lee CH, Subramanian S, Beck AH, et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary［J］. PLoS One，2009，4(10):e7314.

［11］   Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis［J］. Nature，2010，464(7291):1071-1076.

［12］   Qiu JJ, Lin YY, Ye LC, et al. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer［J］. Gynecol Oncol，2014，134(1):121-128.

［13］   Huang KC, Rao PH, Lau CC,et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy［J］.Mol Cancer Ther，2002，1(10):769-776.

［14］   Prat J. Ovarian carcinomas:five distinct diseases with different origins, genetic alterations, and clinicopathological features［J］. Virchows Arch,2012，460:237-249.

（2014-11-16收稿）

[1]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(5): 481-483.
[2]	LI Yi-fan, LI Ning, WU Ling-ying. Treatment for recurrent platinum-resistant epithelial ovarian carcinoma. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(5): 503-507.
[3]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(3): 301-309.
[4]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(3): 310-318.
[5]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(1): 56-65.
[6]	CAO Dong-yan, XIANG Yang. Quality control of surgery for ovarian cancer. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(1): 29-32.
[7]	ZHANG Qing-quan, WANG Shi-jun. Quality control of surgery for endometrial cancer. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(1): 25-27.
[8]	. [J]. Acta Metallurgica Sinica, 2021, 37(8): 826-831.
[9]	. [J]. Acta Metallurgica Sinica, 2021, 37(7): 731-739.
[10]	. [J]. Acta Metallurgica Sinica, 2021, 37(6): 601-604.
[11]	GAO Qing-lei. Ovarian cancer and normalization of gene detection. [J]. Acta Metallurgica Sinica, 2021, 37(6): 605-609.
[12]	HUANG He，FENG Yan-ling，LIU Ji-hong. Primary and interval cytoreductive surgery for ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 609-613.
[13]	DOU Sha，LI Yi，CUI Heng. First-line chemotherapy for newly diagnosed epithelial ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 613-616.
[14]	CHEN Yu-lian，SHI Ting-yan，ZANG Rong-yu. Problems related to surgery for platinum-sensitive relapsed ovarian cancer and standardized diagnosis and treatment. [J]. Acta Metallurgica Sinica, 2021, 37(6): 616-620.
[15]	DENG Li，LIANG Zhi-qing. Application and controversy of minimally invasive surgery in the treatment of ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 620-623.